Metformin Enhances TKI-Afatinib Cytotoxic Effect, Causing Downregulation of Glycolysis, Epithelial–Mesenchymal Transition, and EGFR-Signaling Pathway Activation in Lung Cancer Cells

The combination of metformin and TKIs for non-small cell lung cancer has been proposed as a strategy to overcome resistance of neoplastic cells induced by several molecular mechanisms. This study sought to investigate the effects of a second generation TKI afatinib, metformin, or their combination on three adenocarcinoma lung cancer cell lines with different EGFRmutation status. A549, H1975, and HCC827 cell lines were treated with afatinib, metformin, and their combination for 72 h. Afterwards, several parameters were assessed including cytotoxicity, interactions, apoptosis, and EGFR protein levels at the cell membrane and several glycolytic, oxidative phosphorylation (OXPHOS), and EMT expression markers. All cell lines showed additive to synergic interactions for the induction of cytotoxicity caused by the tested combination, as well as an improved pro-apoptotic effect. This effect was accompanied by downregulation of glycolytic, EMT markers, a significant decrease in glucose uptake, extracellular lactate, and a tendency towards increased OXPHOS subunits expression. Interestingly, we observed a better response to the combined therapy in lung cancer cell lines A549 and H1975, which normally have low affinity for TKI treatment. Findings from this study suggest a sensitization to afatinib therapy by metformin in TKI-resistant lung cancer cells, as well as a reduction in cellular glycolytic phenotype.

[1]  R. Rosell,et al.  Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities , 2021, British Journal of Cancer.

[2]  C. Zhou,et al.  P76.07 Metformin Enhances the Efficacy of EGFR-TKIs in Advanced Non-Small Cell Lung Cancer Patients With Type 2 Diabetes Mellitus , 2021 .

[3]  Xiaozhen Liu,et al.  Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer—an option for overcoming EGFR-TKI resistance , 2021, Translational lung cancer research.

[4]  Shilei Zhang,et al.  Metformin enhances anti-cancer effects of cisplatin in meningioma through AMPK-mTOR signaling pathways , 2020, Molecular therapy oncolytics.

[5]  Hongzhuan Chen,et al.  Metformin Overcomes Acquired Resistance to EGFR TKIs in EGFR-Mutant Lung Cancer via AMPK/ERK/NF-κB Signaling Pathway , 2020, Frontiers in Oncology.

[6]  C. Chen,et al.  Molecular Profiling of Afatinib-Resistant Non-Small Cell Lung Cancer Cells in vivo Derived from Mice. , 2020, Pharmacological research.

[7]  M. Meyerson,et al.  Genetic ancestry contributes to somatic mutations in lung cancers from admixed Latin American populations , 2020, medRxiv.

[8]  Ashish,et al.  Pyruvate Kinase M2 and Cancer: The Role of PKM2 in Promoting Tumorigenesis , 2020, Frontiers in Oncology.

[9]  E. Nadal,et al.  Exploiting metabolic vulnerabilities of Non Small Cell Lung Carcinoma. , 2020, Seminars in cell & developmental biology.

[10]  Joe Y. Chang,et al.  Metabolic Responses to Metformin in Inoperable Early-stage Non–Small Cell Lung Cancer Treated With Stereotactic Radiotherapy , 2020, American journal of clinical oncology.

[11]  Zhuang Yu,et al.  Synergistic effect of metformin and EGFR-TKI in the treatment of non-small cell lung cancer , 2020, Translational cancer research.

[12]  Xuan Zhu,et al.  EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies , 2019, Front. Oncol..

[13]  R. Rosell,et al.  Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Phase 2 Randomized Clinical Trial. , 2019, JAMA oncology.

[14]  Qi Zhou,et al.  Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial , 2019, Clinical Cancer Research.

[15]  O. Arrieta,et al.  National Clinical Practice Guidelines for the management of non-small cell lung cancer in early, locally advanced and metastatic stages. Extended version. , 2019, Salud publica de Mexico.

[16]  Z. Shao,et al.  The Prognostic Role of Ribosomal Protein S6 Kinase 1 Pathway in Patients With Solid Tumors: A Meta-Analysis , 2019, Front. Oncol..

[17]  Zhongwei Liu,et al.  Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo , 2019, Archives of Toxicology.

[18]  R. Rosell,et al.  Co-mutations in EGFR driven non-small cell lung cancer , 2019, EBioMedicine.

[19]  B. Goh,et al.  Metabolic reprogramming of oncogene-addicted cancer cells to OXPHOS as a mechanism of drug resistance , 2018, Redox biology.

[20]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[21]  Yong He,et al.  Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway , 2018, Biologics : targets & therapy.

[22]  W. Gong,et al.  Metformin sensitizes lung cancer cells to treatment by the tyrosine kinase inhibitor erlotinib , 2017, Oncotarget.

[23]  Yong Liu,et al.  Metformin partially reverses the carboplatin-resistance in NSCLC by inhibiting glucose metabolism , 2017, Oncotarget.

[24]  Ke Chen,et al.  Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF1‐dependent pathway , 2017, Molecular oncology.

[25]  S. Hawley,et al.  Mechanisms of Paradoxical Activation of AMPK by the Kinase Inhibitors SU6656 and Sorafenib , 2017, Cell chemical biology.

[26]  E. Tsiani,et al.  Metformin in Lung Cancer: Review of in Vitro and in Vivo Animal Studies , 2017, Cancers.

[27]  K. Xie,et al.  Progress in the application and mechanism of metformin in treating non-small cell lung cancer , 2017, Oncology letters.

[28]  Lin-lin Sun,et al.  2-Deoxyglucose Suppresses ERK Phosphorylation in LKB1 and Ras Wild-Type Non-Small Cell Lung Cancer Cells , 2016, PloS one.

[29]  S. Ashton,et al.  Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma , 2016, Oncotarget.

[30]  A. Cardona,et al.  Metformin use and its effect on survival in diabetic patients with advanced non-small cell lung cancer , 2016, BMC Cancer.

[31]  C. la Vecchia,et al.  Risk factors for lung cancer worldwide , 2016, European Respiratory Journal.

[32]  F. Ciardiello,et al.  Mechanisms of resistance to EGFR-targeted drugs: lung cancer , 2016, ESMO Open.

[33]  Xuan Liang,et al.  Metformin inhibits growth of human non-small cell lung cancer cells via liver kinase B-1-independent activation of adenosine monophosphate-activated protein kinase , 2016, Molecular medicine reports.

[34]  Yuhchyau Chen,et al.  IL-6 promotes growth and epithelial-mesenchymal transition of CD133+ cells of non-small cell lung cancer , 2015, Oncotarget.

[35]  Zhiqiang Wang,et al.  Metformin inhibits growth of lung adenocarcinoma cells by inducing apoptosis via the mitochondria-mediated pathway. , 2015, Oncology letters.

[36]  M. Stoppelli,et al.  Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.

[37]  H. Esumi,et al.  Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma , 2015, The Journal of Biological Chemistry.

[38]  Matthew Meyerson,et al.  Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP) , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[39]  Zhijun Luo,et al.  MLK3 Phophorylates AMPK Independently of LKB1 , 2015, PloS one.

[40]  M. Tsao,et al.  Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. , 2015, Translational lung cancer research.

[41]  Kuen-Feng Chen,et al.  Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A , 2014, Oncotarget.

[42]  A. Ullrich,et al.  Metformin and salinomycin as the best combination for the eradication of NSCLC monolayer cells and their alveospheres (cancer stem cells) irrespective of EGFR, KRAS, EML4/ALK and LKB1 status , 2014, Oncotarget.

[43]  M. V. Heiden,et al.  Understanding the complex-I-ty of metformin action: limiting mitochondrial respiration to improve cancer therapy , 2014, BMC Biology.

[44]  M. Pollak,et al.  Metformin directly acts on mitochondria to alter cellular bioenergetics , 2014, Cancer & metabolism.

[45]  H. Esumi,et al.  Epidermal Growth Factor Receptor (EGFR) Signaling Regulates Global Metabolic Pathways in EGFR-mutated Lung Adenocarcinoma* , 2014, The Journal of Biological Chemistry.

[46]  H. Long,et al.  Metformin Inhibits the IL-6-Induced Epithelial-Mesenchymal Transition and Lung Adenocarcinoma Growth and Metastasis , 2014, PloS one.

[47]  Yong He,et al.  Metformin Sensitizes EGFR-TKI–Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal , 2014, Clinical Cancer Research.

[48]  I. Pernicova,et al.  Metformin—mode of action and clinical implications for diabetes and cancer , 2014, Nature Reviews Endocrinology.

[49]  L. Tang,et al.  Prognostic Significance of AMPK Activation and Therapeutic Effects of Metformin in Hepatocellular Carcinoma , 2013, Clinical Cancer Research.

[50]  S. Ravera,et al.  Metformin Impairs Glucose Consumption and Survival in Calu-1 Cells by Direct Inhibition of Hexokinase-II , 2013, Scientific Reports.

[51]  Erika Martinelli,et al.  Synergistic Effects of Metformin Treatment in Combination with Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, in LKB1 Wild-type NSCLC Cell Lines , 2013, Clinical Cancer Research.

[52]  J. Christensen,et al.  Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non–Small Cell Lung Cancer with T790M Resistance Mutation , 2012, Molecular Cancer Therapeutics.

[53]  A. Iwama,et al.  Antiproliferative action of metformin in human lung cancer cell lines. , 2012, Oncology reports.

[54]  N. Ridgway,et al.  Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. , 2011, Journal of thoracic disease.

[55]  Y. Maehara,et al.  Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[56]  Jianxing He,et al.  Epithelial mesenchymal transition and lung cancer. , 2010, Journal of thoracic disease.

[57]  B. Viollet,et al.  Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. , 2010, The Journal of clinical investigation.

[58]  P. Goodwin,et al.  Metformin in breast cancer: time for action. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  R. Shaw,et al.  LKB1 and AMP‐activated protein kinase control of mTOR signalling and growth , 2009, Acta physiologica.

[60]  Dario R Alessi,et al.  Metformin and reduced risk of cancer in diabetic patients , 2005, BMJ : British Medical Journal.

[61]  R. Baxter,et al.  Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. , 2003, The Journal of clinical endocrinology and metabolism.

[62]  E. Imyanitov,et al.  EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer. , 2019, Biochimica et biophysica acta. Reviews on cancer.

[63]  芦沼 宏典.  Antiproliferative action of metformin in human lung cancer cell lines , 2012 .

[64]  L. Ger,et al.  [Risk factors of lung cancer]. , 1992, Journal of the Formosan Medical Association = Taiwan yi zhi.